Senior Director, Communications & Corporate Affairs. Website. Track Theratechnologies Inc. com uses cookies on this site. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on. (2020-11-03 | TSX:TH) Theratechnologies Announces Departure of Chief Commercial Officer. com uses cookies on this site. Phone Number (514) 336-7800. com uses cookies on this site. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650For the three- and six-month periods ended May 31, 2023, consolidated revenue was $17,549,000 and $37,457,000, compared to $19,268,000 and $37,825,000 for the same periods ended May 31, 2022. Theratechnologies (TSX:TH)has indicated that Trogarzo did not meet its primary endpoints in its IM method study. (Translation of registrant’s name into English) 2310 Alfred-Nobel Boulevard . US Headquarters. The company offers EGRIFTA and EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies’ CFO to Attend Cantor Global Healthcare Conference in New York City. When this page refreshes you will be logged in with the new address. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced it will report financial results and provide a business update for its second. Stockhouse. Biopharmaceutical company Theratechnologies Inc. 71%. Thank you. (Translation of registrant’s name into English) 2310 Alfred-Nobel Boulevard . TO) Stock Price, News, Quote & History - Yahoo Finance Canada Markets close in 43 mins S&P/TSX 20,125. $103. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and. The firm offers its product under the brand name of. Cookies are used to offer you a better browsing experience and to. TO) stock quote, history, news and other vital information to help you with your stock trading and investing. Last Reviewed: February 24, 2023. Betteryear2. Register for your free account today at data. This work is well underway and will be considered by the SAC as part of their meeting, which is scheduled for the latter half of March when the analyses are expected to be ready. Find the latest Theratechnologies Inc. MONTREAL, April 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. By continuing to use our service, you agree to our use of cookies. home message. MONTREAL, July 07, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that President and CEO, Paul Lévesque has issued an open letter to. Further information about Theratechnologies is available on the Company's website at , on SEDAR at and on. By continuing to use our service, you agree to our use of cookies. Theratechnologies last announced its earnings data on September 26th, 2023. Investor Relations. European Headquarters. com uses cookies on this site. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced today that it will report financial results. 2% for this period. com. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has established an at-the-market ("ATM") equity program allowing Theratechnologies to issue and sell up to US $50 million common shares from. The company reported ($0. . Theratechnologies Inc. 4. 19, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Stockhouse. NEW YORK, Dec. com uses cookies on this site. We also use them to share usage. stock price gained 6. BioSyent then managesthese products through the regulatory process and product registration (approval); and once approved, BioSyent markets these products throughout Canada. 12, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. . (Image via Theralase Technologies Inc. 30, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Stockhouse. Theratechnologies (TH) has submitted a supplemental biologics license application (sBLA) to the U. We also use them to share usage. Theratechnologies (TH) has announced preclinical findings for its peptide-drug conjugate TH1902 for the treatment of metastatic cancers. Theratechnologies inc. VANCOUVER, British Columbia, Nov. Theratechnologies’ R&D staff is bearing the brunt of. Amount of cash a business has after it has met its financial obligations such as debt and outstanding payments. By continuing to use our service, you agree to our use of cookies. 9 million, adjusted EBITDA of $2. View recently published Stock News reports from independent reports and journalists. The money will be used to grow the company’s FDA-approved drugs, Egrifta SV (tesamorelin), used for the reduction of excess. GlobeNewswire. The financial results presented in this press release are taken from the. 26 +15. Theratechnologies Inc. The Company currently commercializes two products in the field of HIV. 04, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that all five of the U. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Wainwright NASH Investor Conference. 15, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TSX: TH, Forum) has long been a favourite among Healthcare Bullboard posters who have been following its developments to commercialize innovative therapies. We currently market prescription products for people with. (2021-03-20 | TSX:TH) Theratechnologies Announces New Data Demonstrating Tesamorelin's Positive Effect on Immune Response Linked to Liver Inflammation. T. Conjugating the short peptide with various anti-cancer agents allows for. MONTREAL, Oct. 75. H4S 2B4 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F x Form 40-F ¨Amendments Allow Theratechnologies to Maintain Minimum Liquidity of US$15 Million up to and until October 31, 2023. 65 per cent to C$1. MONTREAL, Feb. stock news by MarketWatch. Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the. MONTREAL, Sept. com uses cookies on this site. Headquartered in Montreal, Quebec (Canada), Theratechnologies commercializes two medicines in HIV and has research programs in HIV, NASH and Oncology. TH | March 7, 2023. : 001-35203 Mr. D. 9 million and US. 4. 8. Theratechnologies Reports Financial Results for the Third Quarter and Nine Months of Fiscal 2023 and Provides Business Updates. 00%. com uses cookies on this site. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic. Cookies are used to offer you a better browsing experience and to analyze our traffic. (Translation of registrant’s name into English) 2310 Alfred-Nobel Boulevard . Find more information. 5000 0. -based clinical sites participating in the conduct of the Phase. Theratechnologies Inc. - Cash, bonds and money market funds of US$22. MONTREAL, April 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. By continuing to use our service, you agree to our use of cookies. 9%, while the Biotechs industry saw earnings growing at 17. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650 [email protected] Inc. MONTREAL, Oct. Stockhouse. Theratechnologies (TSX: TH) has posted net revenue estimates for fourth quarter and the full fiscal year ending Nov 30, 2020. - October 10, 2023) - KO Gold Inc. (TSX: EXRO) (OTCQB: EXROF) (the "Company" or "Exro" ), a leading clean technology company which has developed a new class of power electronics for electric motors and powertrains, announced today its financial results for the three months ended March 31, 2022. Stockhouse. Theratechnologies affirms fiscal 2022 revenue to be in the range of $79 million and $84 million for full fiscal 2022, or growth of the commercial portfolio to be in the range of 13% and 20% as compared to the 2021 fiscal year. Theratechnologies Inc. Approximately US$2,000,000, or CA$2,600,000, was paid in cash at closing. (2021-01-11 | TSX:TH) Theratechnologies Announces US$40 Million Bought-Deal Public Offering of Units. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Gain a better understanding of ETFs with our ETF Insights and ETF 101 resource. FAQ – Émetteurs inscrits NOUVEAU. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a commercial-stage biopharmaceutical company addressing unmet medical needs by bringing to market specialized therapies for people with orphan medical. com. Theratechnologies (TSX:TH)has indicated that Trogarzo did not meet its primary endpoints in its IM method study. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that new data featuring its investigational sortilin 1 (SORT1)-targeting peptide-drug conjugate technology will be presented in three posters at the American. Theratechnologies's earnings have been declining at an average annual rate of -35. 49) by $0. Theratechnologies Announces Finalization of Amendments to Some of the Terms and Conditions of its Credit Agreement with Marathon;. MONTREAL, April 08, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Stockhouse. We currently market prescription products for people with HIV in the United States. Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. Stockhouse. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company will present data from tissue microarrays showing high. com uses cookies on this site. This module allows you to check different measures of market premium (i. MONTREAL, Oct. It also helps investors analyze the systematic and unsystematic risks associated with investing in Theratechnologies over a specified time horizon. 00 to $36. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 00, suggesting a possible upside of. C. Theratechnologies layoffs. MONTREAL, Nov. MONTREAL, Oct. Jours fériés des marchés. By continuing to use our service, you agree to our use of cookies. It’s lead investigational peptide drug conjugate linked to docetaxel, a well-established and well-characterized cytotoxic agent used in the treatment of. (TSX: TH) announced today that the Supreme Court of Canada has granted its appeal and dismissed 121851 Canada Inc. (2021-11-03 | TSX:TH) Theratechnologies to Present at the Credit Suisse 30th Annual Healthcare Conference on November 11, 2021. Cookies are used to offer you a better browsing experience and to analyze our traffic. Theratechnologies Announces 1-for-4 Reverse Stock Split. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies Announces Certain Preliminary Q3 2023 Financial Highlights. We also use them to share usage. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. MONTREAL, July 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. US Headquarters. Stockhouse. Theratechnologies Appoints New Board Member. For investor inquiries: Leah Gibson. (THTX) NasdaqCM - NasdaqCM Real Time Price. com uses cookies on this site. , alpha and beta) for all equities such as Theratechnologies. , that crews have been mobilized to prepare for the 2022 exploration program at the Treaty Creek property, located in the heart of the. licensed the product from TaiMed Biologics, Inc. Cookies are used to offer you a better browsing experience and to analyze our traffic. This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its. com. H. stockhouse. See the latest Theratechnologies Inc stock price (THTX:XNAS), related news, valuation, dividends and more to help you make your investing decisions. By continuing to use our service, you agree to our use of cookies. 23) earnings per share over the last year ( ($1. 13, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. com uses cookies on this site. Track Theratechnologies Inc. F8 formulation intended to replace EGRIFTA SV® with simplified dosing for the treatment of excess abdominal fat in adults with HIV and lipodystrophy. 12, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. . La Bourse de Toronto a perdu. is an employee of TaiMed Biologics USA, Inc. com uses cookies on this site. The SORT1 receptor plays a significant role in protein internalization, sorting and trafficking. A live webcast of Dr. Further. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that President and CEO, Paul Lévesque has issued an open letter to shareholders. Cookies are used to. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its third quarter 2023 financial results on Thursday, November 9, 2023 prior to market opening. Theratechnologies to Present at the Credit Suisse 30th Annual Healthcare Conference on November 11, 2021 Globe Newswire - Wed Nov 3, 2021 . Type: Company - Public (TH) Revenue: $5 to $25 million (USD) Biotech & Pharmaceuticals. Shares of Theratechnologies are up 4. Theratechnologies Provides Details About R&D Day Webcast. 23 to a day high of $1. Denis Boucher. Theratechnologies has generated ($1. By continuing to use our service, you agree to our use of cookies. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies,. (882) posted 3 minutes ago. Theratechnologies is pepped up on peptides. 06 million, an increase of. The Notes were issued under a trust indenture dated as of June 19, 2018, by and among Theratechnologies and Computershare Trust Company of Canada. Get the latest Theratechnologies Inc (THTX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. T. MONTREAL, July 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced dosing of the first participant in Part 3 of its Phase 1 clinical trial of. 's motion for leave to commence. L. com uses cookies on this site. Cookies are used to offer you a better browsing experience and to analyze our traffic. Stockhouse. By continuing to use our service, you agree to our use of cookies. When this page refreshes you will be logged in with the new address. (TSX:TH) announced new data from a tissue microarrays study which demonstrated high expression of sortilin 1 in solid tumors. Further. The reported ($0. 06 million, an increase of 14. Cookies are used to offer you a better browsing experience and to analyze our. During the last trading day the stock fluctuated 4. It's a different kind of fat that may require a different type of treatment. is a pharmaceutical company. Theratechnologies Inc. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 9% more than in 2021. $109. (“Theratechnologies”) with the Securities and Exchange Commission (the. Theratechnologies Announces Fiscal Year 2023 Guidance and Operating Plan’s Key Objectives. October 13, 2022 07:30 ET | Source: Theratechnologies. MONTREAL, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. TH | February 28, 2023. 74M. Amendment Withdraws the Condition to File HFS Report to the FDA to Access the US$20 Million Second Tranche. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650 [email protected] is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. : Renegotiated Lease to Generate Substantial Annual Savings Stockhouse. Theratechnologies Stock Price, News and Company Updates. Cookies are used to offer you a better browsing experience and to analyze our traffic. Ibalizumab-uiyk (Trogarzo) is a medical infusion treatment for HIV infection in adults for whom other HIV medicines have not worked. Montreal-based biopharmaceutical company Theratechnologies Inc. 3 brokerages have issued 1-year price objectives for Theratechnologies' shares. Biopharma Theratechnologies (NASDAQ:THTX) Friday announced that a study evaluating an intramuscular (IM) method of administration for its therapy, Trogarzo, did not meet the primary endpoint. stock news by MarketWatch. TMX Group Limited and its affiliates do not endorse or recommend any securities issued by any companies identified on, or linked through, this site. La Bourse de Toronto a clôturé en hausse mardi pour une troisième séance consécutive, tandis que les grands indices boursiers américains ont avancé eux aussi. com. (2022-02-24 | TSX:TH) Theratechnologies Reports Financial Results for Fiscal 2021 and Provides Business Update. 89 $2. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has closed its previously announced publi. com uses cookies on this site. 10% least volatile stocks in CA Market. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650 [email protected] Inc. Vice President, Communications and Corporate Affairs. Stockhouse. 35 as of 10:41 a. (2021-05-31 | TSX:TH) Theratechnologies Hires Vice President, Human Resources. 04) earnings per share (EPS) for the quarter. Investor inquiries: Elif McDonald. (2020-10-16 | TSX:TH) Theratechnologies Appoints Two New Board Members. 1300 (+9. View real-time stock prices and stock quotes for a full financial overview. View real-time stock prices and stock quotes for a full financial overview. 6. By continuing to use our service, you agree to our use of cookies. 08). 124. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. - Q3 2022 Consolidated Revenue Growth of 17% to $20. (2022-07-27 | TSX:TH) Theratechnologies Announces Closing of Funding of $40 Million Under the Terms of its Credit Agreement Stockhouse. The ADRIQ (Association pour le développement de la recherche et de l’innovation du Québec) rewards Quebec-based companies for leadership and innovation in their respective. (NASDAQ:NASDAQ:THTX) Q3 2022 Earnings Conference Call October 13, 2022 8:30 AM ETCompany ParticipantsElif McDonald - Head of Investor RelationsPaul Levesque -. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies,. TORONTO, May 19, 2023 /CNW/ - This press release is being disseminated as required by. (TSX: TH, Forum) noted that its Q1 2022 consolidated sales grew 20%, supported by 35% growth in sales of EGRIFTA SV formulation. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, reported the voting results from its annual meeting of shareholders held today in a virtual-only setting. Cookies are used to offer you a better browsing experience and to analyze our traffic. Find the latest Theratechnologies Inc. Free cash flow. (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its fourth quarter and full year fiscal 2022 ended November 30, on Tuesday, February 28, 2023. Biopharmaceutical company Theratechnologies (TH) has closed its bought deal public offering after raising over C$58 million in proceeds. (882) posted 3 minutes ago. 18% on the last trading day (Wednesday, 25th Oct 2023), rising from $1. Amendments Allow Theratechnologies to Maintain Minimum Liquidity of US$15 Million up to and until October 31, 2023. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update. Theratechnologies inc. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has closed its previously announced publi. Theratechnologies Announces Certain Preliminary Q3 2023 Financial Highlights. Stockhouse. TH | October 13, 2022. FY2022 top line revenue expected to end the year at ~$80 million, in line with previously announced revenue guidance; FY2023 revenue guidance range set between $90 million and $95 million, ending the new year on a solid path to positive cash. com uses cookies on this site. Biopharmaceutical company Theratechnologies Inc. . Cookies are used to offer you a better browsing experience and to. Stockhouse. 31K. (2022-10-03 | TSX:TH) Theratechnologies' Trogarzo® Approved by FDA for 30-Second Intravenous (IV) Push, Simplifying HIV Treatment for Heavily Treatment-Experienced Population. (2019-08-07 | TSX:TH) Jean-Denis Talon Retires From Theratechnologies' Board of Directors. com. 04) earnings per share (EPS) for the quarter. By continuing to use our service, you agree to our use of cookies. 67% from the latest price. 5000 +0. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has decided to pause the enrollment of patients in its Phase 1 clinical. (2020-03-31 | tsx:th) theratechnologies provides business update related to current covid-19 situation Stockhouse. (2022-09-19 | TSX:TH) Theratechnologies to Present at the Cantor Oncology, Hematology & HemeOnc Conference. View analysts price targets for THTX. Cookies are used to offer you a better browsing experience and to analyze our traffic. (2018-12-03 | TSX:TH) Theratechnologies Appoints New Chief Commercial Officer. (2019-08-12 | TSX:TH) Theratechnologies Files Application to List on NASDAQ. With the company starting 2023 with 8,725 employees, that’s an 11. Stockhouse. . By continuing to use our service, you agree to our use of cookies. 72%. By exploiting the SORT1 function in ligand internalization, a new anticancer treatment strategy was designed to target SORT1‐positive TNBC‐derived cells both in vitro and in two in vivo tumor xenografts. Whether TH1902 impacts the chemoresistance phenotype of human triple-negative breast CSC. The Montreal-based biopharmaceutical company's consolidated net revenues for fourth quarter 2020 are expected to be between US$18. 40%) (As of 11/17/2023 ET) Compare Today's Range $1. 18, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. MONTREAL, July 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies Inc. " The 12-month stock price forecast is $18. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a. ET. 1-438. GlobeNewswire. com uses cookies on this site. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development. According to 3 analysts, the average rating for THTX stock is "Buy. We also use them to share usage information with our partners. TH | July 20, 2023. communications@theratech. a biopharmaceutical company focused on the development and commercialization of innovative therapies, today initiated enrollment of patients in the basket portion of the first-in-human study of TH1902, Theratechnologies’ investigational lead peptide drug conjugate (PDC) for the treatment of sortilin-expressing. We also use them to share usage information with our partners. 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. com uses cookies on this site. We currently market prescription products for people with HIV in the United States. Trogarzo® and. Stockhouse. Get the latest Theratechnologies Inc (THTX) real-time quote, historical performance, charts, and other financial information to help you make more informed. July 24 - Heron Therapeutics: Heron is turning to layoffs for the second time in 13 months to cut. It is the Company’s proprietary peptide linked to. By continuing to use our service, you agree to our use of cookies. Agreement in principle on key amendments to loan. View real-time stock prices and stock quotes for a full financial overview. About Theratechnologies Theratechnologies (Nasdaq: THTX) (TSX: TH) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. By continuing to use our. MONTREAL, June 30, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 04, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its third quarter of fiscal 2022 ended August 31, on Thursday, October 13. - Q3 2022 Consolidated. L. The website address for Stockhouse has changed We changed the address of the Stockhouse website from to stockhouse. T. P. Theratechnologies Appoints New Board Member. Theratechnologies Inc. TH | July 20, 2023. Register for your free account today at data. Northwest also announces an update on its. By continuing to use our service, you agree to our use of cookies. Unveiling Silvercorp's golden potential at the Ying Mining District. MONTREAL, Nov. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. -4. By continuing to use our service, you agree to our use of cookies. Company Description: Theratechnologies is pepped up on peptides. Theratechnologies (TSX:TH) has announced a loan of up to US$100M from Marathon Asset Management. ir@theratech. MONTREAL, March 07, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 24, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Further. Small cap stock market news and analysis, portfolio tracking, investor message boards and forums (bullboards), newsletter aggregation and detailed snapshots of stock quotes for. 3089 Background: SORT1 is expressed in a variety of tumors when compared to most healthy tissue. By continuing to use our service, you agree to our use of cookies.